We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00520325
Recruitment Status : Withdrawn (Sponsor decision to terminate the study)
First Posted : August 24, 2007
Last Update Posted : September 5, 2012
Information provided by:
Enzon Pharmaceuticals, Inc.

Brief Summary:
The goal of this clinical research study is to find the dose of EZN-2232 that can be given to MBL deficient pediatric cancer patients undergoing chemotherapy. The pharmacokinetics, pharmacodynamics, and safety of the study drug will also be studied.

Condition or disease Intervention/treatment Phase
Cancer Hematologic Diseases Fever Neutropenia Drug: Intravenous recombinant human mannose binding lectin Phase 1

Detailed Description:
MBL deficient patients will be randomized in a ratio of 1:1 to receive a single dose of either 0.5 mg/kg or 1.0 mg/kg of intravenous rhMBL. A total of 24 patients will be treated in each of the rhMBL arms, (12 in the 0.5 mg/kg and 12 in the 1.0 mg/kg. All patients are to receive anti-infectious prophylactic supportive therapy as per institutional standards

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics, and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia
Study Start Date : June 2007
Primary Completion Date : June 2009
Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever
U.S. FDA Resources

Arm Intervention/treatment
0.5 mg/kg Drug: Intravenous recombinant human mannose binding lectin
Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
1.0 mg/kg Drug: Intravenous recombinant human mannose binding lectin
Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Primary Outcome Measures :
  1. Determine the safety and tolerability of intravenous rhMBL administered at dosages of 0.5 and 1.0 mg/kg to MBL deficient pediatric hematology/oncology patients during episodes of fever and neutropenia. [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. Determine the PK profile of intravenous rhMBL as a single dose escalation cohort design in MBL deficient pediatric oncology patients during episodes of fever and neutropenia. [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: Patients must meet all of the following criteria to be eligible for enrollment into the study:

  • Children ages 2 to 17 receiving chemotherapy for hematological/oncological diseases.
  • Patients must have documented MBL levels <300 ng/mL in serum as evaluated in the screening protocol.
  • Fever defined as an oral temperature equivalent of >100.4°F (38°C).
  • Neutropenia defined as an absolute neutrophil count ≤1,000/mm3 with the anticipation that the counts will fall below 500/mm3.
  • Receiving broad spectrum antibiotics for fever and neutropenia.
  • Patients with age-adjusted normal serum creatinine OR a creatinine clearance >60 mL/min/1.73m2.
  • Informed consent of the patient, parent or legally authorized representative obtained prior to entry.
  • Reliable and willing to make themselves available for the duration of the study and to abide by the study restrictions.

Exclusion Criteria: Patients meeting any of the following exclusion criteria will not be eligible for enrollment.

  • Patients receiving the preparative regimen for a bone marrow or hematopoietic stem cell transplantation.
  • Concurrent serious illness in the opinion of the principal investigator that could potentially interfere with protocol compliance.
  • Patient is pregnant, breast feeding or planning a pregnancy during the course of the study.
  • Sexually active male and female patients not using an acceptable barrier method of contraception or practicing abstinence throughout the study and for at least 30 days after receiving their last treatment unless the patient is surgically or medically sterile.
  • Patients with moderate or severe liver disease, as defined by:

AST or ALT >5 times upper limit of normal (ULN) OR Total bilirubin >2.5 times ULN.

  • Patients with poor venous access that would preclude intravenous drug delivery or multiple blood draws.
  • Current participation in another clinical study with an investigational agent and/or use of an investigational drug (not including investigational use of an FDA approved drug) in the 30 days before scheduled administration of rhMBL.
  • Known allergic reactions to MBL or other human plasma products.
  • Patients on hemodialysis unable to tolerate the volume of IV fluid on non-dialysis days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00520325

Sponsors and Collaborators
Enzon Pharmaceuticals, Inc.
Principal Investigator: Thomas Walsh, MD NIH/National Cancer Institute

Responsible Party: Nazish Huq, Enzon Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT00520325     History of Changes
Other Study ID Numbers: EZN-2232-03
NCI # 07-C-0027
First Posted: August 24, 2007    Key Record Dates
Last Update Posted: September 5, 2012
Last Verified: February 2009

Keywords provided by Enzon Pharmaceuticals, Inc.:
MBL deficient oncologic hematologic pediatric fever neutropenia

Additional relevant MeSH terms:
Hematologic Diseases
Body Temperature Changes
Signs and Symptoms
Leukocyte Disorders